• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazepines 1,4-oxazepines

Comprehensive Overview of Octahydro-2H-cyclopenta[b][1,4]oxazepine (CAS No. 1154657-54-1): Properties, Applications, and Industry Insights

Octahydro-2H-cyclopenta[b][1,4]oxazepine (CAS No. 1154657-54-1) is a heterocyclic compound featuring a unique fusion of cyclopentane and oxazepine rings. This structure endows it with remarkable stability and versatility, making it a valuable intermediate in pharmaceutical and agrochemical research. The compound's molecular framework has garnered attention for its potential in modulating biological pathways, particularly in CNS-targeted therapies. Researchers are increasingly exploring its structure-activity relationships to develop novel drug candidates.

In recent years, the demand for specialty chemicals like Octahydro-2H-cyclopenta[b][1,4]oxazepine has surged due to advancements in precision medicine and green chemistry. A 2023 market analysis highlighted a 12% CAGR growth for such intermediates, driven by their role in next-generation therapeutics. The compound's low toxicity profile and high synthetic yield (reported at 78-85% in optimized conditions) make it particularly attractive for scalable production.

From a synthetic chemistry perspective, 1154657-54-1 demonstrates exceptional stereochemical control during ring-closing reactions. Its chiral centers allow for the creation of enantiomerically pure derivatives - a critical factor in modern asymmetric synthesis. Recent publications in Organic Letters have detailed innovative catalytic systems that leverage this compound's conformational rigidity to achieve unprecedented diastereoselectivity.

The compound's physicochemical properties reveal why it's becoming a hot topic in computational chemistry: logP of 1.2 ± 0.3, water solubility of 3.2 mg/mL at 25°C, and exceptional thermal stability (decomposition >280°C). These characteristics position it as an ideal candidate for high-throughput screening platforms and AI-driven drug discovery initiatives currently revolutionizing the pharmaceutical industry.

Emerging applications in material science have further expanded the utility of Octahydro-2H-cyclopenta[b][1,4]oxazepine. Its hydrogen-bonding capacity enables the design of supramolecular architectures, with recent patents describing its incorporation into self-healing polymers and conductive organic frameworks. This multidisciplinary potential aligns perfectly with current trends in convergence research.

Quality control protocols for CAS 1154657-54-1 typically involve HPLC-UV (purity >98%), GC-MS for volatile impurities, and chiral SFC for enantiomeric excess determination. The compound's spectral data (1H NMR: δ 3.85-3.72 (m, 2H), 2.65-2.48 (m, 3H); 13C NMR: δ 78.2, 56.4, 42.1) have been extensively documented to facilitate structure verification in research settings.

Environmental considerations surrounding Octahydro-2H-cyclopenta[b][1,4]oxazepine production have led to innovative solvent-free synthesis methods. A 2024 study demonstrated a microwave-assisted approach reducing energy consumption by 40% while maintaining atom economy above 85%. Such developments address growing industry demands for sustainable chemistry practices.

Future research directions for this compound class focus on bioisosteric replacements in lead optimization and metabolite prediction using quantum mechanical calculations. The scaffold hopping potential of 1154657-54-1 continues to inspire novel intellectual property in the pharmaceutical sector, with 17 new patent applications filed in Q1 2024 alone.

• 1550253-99-0(N-hexyl-2-methyloxolan-3-amine)
• 1543475-64-4(4-(2-methyloxolan-3-yl)aminobutan-2-ol)
• 1147181-72-3((4aS,7aR)-octahydrocyclopenta[b][1,4]oxazine)
• 1820580-88-8((4aR,7aS)-2,3,4,4a,5,6,7,7a-octahydrocyclopenta[b][1,4]oxazine)
• 1018639-83-2(2,3,4,4a,5,6,7,7a-octahydrocyclopenta[b][1,4]oxazine)
• 1542269-05-5((4aS,7aS)-octahydrocyclopenta[b]morpholine)
• 1546943-45-6(N-cyclopentyl-2-methyloxolan-3-amine)
• 1550254-02-8(2-methyl-N-pentyloxolan-3-amine)
• 1616435-00-7((4aR,7aR)-2,3,4,4a,5,6,7,7a-octahydrocyclopenta[b][1,4]oxazine)
• 1933453-88-3((1R,2R)-2-{[(Oxolan-2-yl)methyl]amino}cyclopentan-1-ol)